Allergy Study
Take part in a new research study for a potential new treatment for allergic diseases.
This study aims to evaluate the safety and tolerability of Exl-111 in developing a potential new treatment for various allergy response conditions.
Critical Eligibility Criteria:
To take part in this study, you will need to meet all the following:
- 18-55 years of age
- Suffer from mild or seasonal allergies
- BMI between 18.0 and 32.0
Further eligibility criteria will be assessed during pre-screening and screening.
Commitment:
If you are deemed eligible for the study, your participation is expected to last between 33- 41 weeks. There are two parts to the study which have varying time commitments.
Locations:
Adelaide
If you take part in this research study, there will be:
Paid for your time
You will receive payment for participating in this study
Free study-related medical care
Be among the first to access potential new research treatments before they are widely available.
Expert medical monitoring
Receive top-tier medical care and monitoring from experienced healthcare professionals.
Contribution to medical research
Help investigate a potential new treatment that could improve the lives of individuals with allergy diseases.
Register your interest now
or scroll down to read the study FAQs
Study Guide
01
Who can take part in this study?
-
To take part in this study, you will need to meet all the following (other criteria apply):
- 18-55 years of age
- Suffer from mild or seasonal allergies
- BMI between 18.0 and 32.0
02
Who is unable to take part in this study?
+
Unfortunately, if any of the following apply to you, this study is not the right fit for you:
- If you are currently pregnant
- If you are a heavy smoker
- If you have participated in a clinical trial in the last month
- If you have received anti-IgE therapy prior
- If you have participated in this study already
Please note, additional eligibility criteria apply.
03
What does the study involve for participants?
+
If you are deemed eligible for the study, your participation is expected to last between 33- 41 weeks. There are two parts to the study which have varying time commitments.
Part A contains:
- 1 screening visit
- 5 night inpatient stay and up to 11 follow up visits over 31 weeks
Part B contains:
- 1 screening visit
- 2x 5 night inpatient stays and 2x 3 night inpatient stays and up to 13 outpatient visits over 41 weeks.
Participation in this research is voluntary, and you may withdraw from the study at any time.
04
What is the purpose of this study?
+
This study aims to evaluate the safety and tolerability of Exl-111 in developing a potential new treatment for various allergy response conditions.
05
What is an allergy?
+
An allergy is a response occurring in a person’s body reacting to an allergen. An allergen can be different things such as food allergies, animal/dust allergies and others.*
06
Why is this study important?
+
This study is important because it is developing a potential new treatment that may assist in preventing allergy responses in a more efficient way.
07
Who is sponsoring this study?
+
This study is being sponsored by Excellergy Australia PTY Ltd.
08
Where is my nearest study site?
+
Here is a list of all of the sites for this study:
South Australia
- CMAX Clinical Research - Ground Floor, 21/24 North Terrace, Adelaide SA 5000
09
What if I have other questions about the study?
+
We are here for you! Head to our Evrima Help Centre and search for answers relating to clinical trials, study information and managing your Evrilink account
This study has been approved by an independent Human Research Ethics Committee
Help make medical research breakthroughs happen.
Need help with clinical trial information?
Search our Evrima help Centre for answers related to information about our active studies, information about managing your Evrilink account, and general clinical trial knowledge!
Read our FAQs